Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets

• DOI: 10.1038/s41598-018-24462-4
• Publication Date: 2018-04-13T14:30:53Z
• Authors: Mark A. Travassos; Amadou Niangaly; Jason A. Bailey; Amed Ouattara; Drissa Coulibaly; Kirsten E. Lyke; Matthew B. Laurens; Jozelyn Pablo; Algis Jasinskas; Rie Nakajima; Andrea A. Berry; Matthew Adams; Christopher G. Jacob; Andrew Pike; Shannon Takala-Ha...; Li Liang; Bourema Kouriba; Abdoulaye K. Kone; J. Alexandra Rowe; JoAnn Moulds; Dapa A. Diallo; Ogobara K. Doumbo; Mahamadou A. Thera; Philip L. Felgner; Christopher V. Plowe
• Keywords: Falciparum; Male; 0301 basic medicine; Cerebral; Plasmodium falciparum; Malaria, Cerebral; 610; Antigens, Protozoan; Paediatric research; Article; 03 medical and health sciences; Rare Diseases; Clinical Research; 2.1 Biological and endogenous factors; Humans; Aetiology; Antigens; Malaria, Falciparum; Child; Preschool; Pediatric; Vaccines; Infant; Anemia; Translational research; Brain Disorders; Malaria; 3. Good health; Vector-Borne Diseases; Infectious Diseases; Good Health and Well Being; Case-Control Studies; Child, Preschool; Protozoan; Female; Infection

AbstractVariant surface antigens (VSAs) play a critical role in severe malaria pathogenesis. Defining gaps, or “lacunae”, in immunity to these Plasmodium falciparum antigens in children with severe malaria would improve our understanding of vulnerability to severe malaria and how protective immunity develops. Using a protein microarray with 179 antigen variants from three VSA families as well as more than 300 variants of three other blood stage P. falciparum antigens, reactivity was measured in sera from Malian children with cerebral malaria or severe malarial anaemia and age-matched controls. Sera from children with severe malaria recognized fewer extracellular PfEMP1 fragments and were less reactive to specific fragments compared to controls. Following recovery from severe malaria, convalescent sera had increased reactivity to certain non-CD36 binding PfEMP1s, but not other malaria antigens. Sera from children with severe malarial anaemia reacted to fewer VSAs than did sera from children with cerebral malaria, and both of these groups had lacunae in their seroreactivity profiles in common with children who had both cerebral malaria and severe malarial anaemia. This microarray-based approach may identify a subset of VSAs that could inform the development of a vaccine to prevent severe disease or a diagnostic test to predict at-risk children.